[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.127.188. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
April 5, 2006

Fondaparinux in ST-Segment Elevation Myocardial InfarctionThe Drug, the Strategy, the Environment, or All of the Above?

Author Affiliations
 

Author Affiliation: Duke Clincal Research Institute, Durham, NC.

 

Published online March 14, 2006 (doi:10.1001/jama.295.13.jed60020).

JAMA. 2006;295(13):1579-1580. doi:10.1001/jama.295.13.jed60020

Antithrombotic therapy has become a major defense against the assault of atherosclerosis on society, and accordingly, “atherothrombosis” has become a commonly accepted term in the cardiovascular practice community. Understandably, exploration of the biology of atherothrombosis has led to the development of a variety of drugs intended to block coagulation and thereby prevent arterial thrombosis. The OASIS (Organization to Assess Strategies for Ischemic Syndromes) 6 trial reported in this issue of JAMA by the OASIS-6 Trial Group1 represents another major milestone in this remarkable saga.

First Page Preview View Large
First page PDF preview
First page PDF preview
×